JP2022532173A5 - - Google Patents
Info
- Publication number
- JP2022532173A5 JP2022532173A5 JP2021566504A JP2021566504A JP2022532173A5 JP 2022532173 A5 JP2022532173 A5 JP 2022532173A5 JP 2021566504 A JP2021566504 A JP 2021566504A JP 2021566504 A JP2021566504 A JP 2021566504A JP 2022532173 A5 JP2022532173 A5 JP 2022532173A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- humanized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019086364 | 2019-05-10 | ||
| CNPCT/CN2019/086364 | 2019-05-10 | ||
| PCT/US2020/032095 WO2020231809A1 (en) | 2019-05-10 | 2020-05-08 | Humanized anti-cd137 antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022532173A JP2022532173A (ja) | 2022-07-13 |
| JP2022532173A5 true JP2022532173A5 (enExample) | 2023-05-15 |
| JP7682102B2 JP7682102B2 (ja) | 2025-05-23 |
Family
ID=73289535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566504A Active JP7682102B2 (ja) | 2019-05-10 | 2020-05-08 | ヒト化抗ｃｄ１３７抗体およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11203643B2 (enExample) |
| EP (1) | EP3966252A4 (enExample) |
| JP (1) | JP7682102B2 (enExample) |
| KR (1) | KR20220008306A (enExample) |
| CN (1) | CN114026120B (enExample) |
| AU (1) | AU2020276500A1 (enExample) |
| CA (1) | CA3139274A1 (enExample) |
| WO (1) | WO2020231809A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12024560B2 (en) * | 2017-03-28 | 2024-07-02 | Lyvgen Biopharma Holdings Limited | Therapeutic agents and methods for enhancing immune responses in tumor microenvironment |
| WO2019109238A1 (en) | 2017-12-05 | 2019-06-13 | Lyvgen Biopharma Co., Ltd. | Anti-cd137 antibodies and uses thereof |
| CN117843786A (zh) | 2019-11-19 | 2024-04-09 | 非同（成都）生物科技有限公司 | 人源化4-1bb单克隆抗体及其药物组合物 |
| JP2023549157A (ja) * | 2020-11-10 | 2023-11-22 | リビジェン バイオファーマ ホールディングス リミテッド | 抗ｃｄ１３７結合分子を含む二重特異性抗体 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303121B1 (en) * | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
| KR20000034847A (ko) * | 1998-11-17 | 2000-06-26 | 성재갑 | 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물 |
| AU2002364935A1 (en) | 2001-10-09 | 2003-06-23 | Mayo Foundation For Medical Education And Research | Enhancement of immune responses by 4-1bb-binding agents |
| US20030223989A1 (en) | 2002-04-18 | 2003-12-04 | Pluenneke John D. | CD137 agonists to treat patients with IgE-mediated conditions |
| JP2006500921A (ja) * | 2002-07-30 | 2006-01-12 | ブリストル−マイヤーズ スクイブ カンパニー | ヒト４−１ｂｂに対するヒト化抗体 |
| US7288638B2 (en) * | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| CN1997667A (zh) * | 2004-05-10 | 2007-07-11 | 宏观基因有限公司 | 人源化FcγRⅡB特异性抗体及其使用方法 |
| US20070253961A1 (en) | 2004-06-09 | 2007-11-01 | Ulsan Industrial Education Foundation | Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis |
| US20060171929A1 (en) * | 2005-01-31 | 2006-08-03 | The University Of Washington | Regulation of dendritic cell functions by the DCAL-2 receptor |
| CN103665168A (zh) | 2005-06-03 | 2014-03-26 | 持田制药株式会社 | 抗cd14抗体融合蛋白质 |
| EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| WO2014055967A2 (en) * | 2012-10-05 | 2014-04-10 | Neotope Biosciences Limited | Compositions and methods for treating diseases of protein aggregation involving ic3b deposition |
| CN104250302B (zh) * | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| WO2015179236A1 (en) | 2014-05-21 | 2015-11-26 | Pfizer Inc. | Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer |
| EP3183269A2 (en) | 2014-08-22 | 2017-06-28 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
| CA3002588C (en) | 2015-10-23 | 2021-11-23 | Apogenix Ag | Single-chain cd137-receptor agonist proteins |
| CN106699889A (zh) | 2015-11-18 | 2017-05-24 | 礼进生物医药科技（上海）有限公司 | 抗pd-1抗体及其治疗用途 |
| US10875921B2 (en) | 2016-05-27 | 2020-12-29 | Abbvie Biotherapeutics Inc. | Anti-4-1BB antibodies and their uses |
| EP3515951B1 (en) * | 2016-09-23 | 2024-02-28 | Merus N.V. | Binding molecules that modulate a biological activity expressed by a cell |
| SG11201906319XA (en) * | 2017-01-20 | 2019-08-27 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd137+ cells |
| US12024560B2 (en) * | 2017-03-28 | 2024-07-02 | Lyvgen Biopharma Holdings Limited | Therapeutic agents and methods for enhancing immune responses in tumor microenvironment |
| US20200199247A1 (en) * | 2017-06-07 | 2020-06-25 | Silverback Therapeutics, Inc. | Antibody conjugates of immune-modulatory compounds and uses thereof |
| WO2019109238A1 (en) * | 2017-12-05 | 2019-06-13 | Lyvgen Biopharma Co., Ltd. | Anti-cd137 antibodies and uses thereof |
| CN107982538B (zh) * | 2017-12-26 | 2021-10-22 | 深圳市体内生物医药科技有限公司 | 一种药物组合物及其应用 |
| CN113039201A (zh) * | 2018-09-28 | 2021-06-25 | 礼进生物医药科技（上海）有限公司 | 具有经过工程化的Fc结构域的抗CD137结合分子及其治疗用途 |
| TWI839395B (zh) * | 2018-10-09 | 2024-04-21 | 瑞士商Ｎｕｍａｂ治療公司 | 靶向cd137的抗體及其使用方法 |
-
2020
- 2020-05-08 CA CA3139274A patent/CA3139274A1/en active Pending
- 2020-05-08 WO PCT/US2020/032095 patent/WO2020231809A1/en not_active Ceased
- 2020-05-08 CN CN202080021830.6A patent/CN114026120B/zh active Active
- 2020-05-08 EP EP20804799.3A patent/EP3966252A4/en active Pending
- 2020-05-08 JP JP2021566504A patent/JP7682102B2/ja active Active
- 2020-05-08 AU AU2020276500A patent/AU2020276500A1/en active Pending
- 2020-05-08 KR KR1020217040560A patent/KR20220008306A/ko active Pending
-
2021
- 2021-03-19 US US17/206,730 patent/US11203643B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| JP6518005B2 (ja) | Ｐｄ−ｌ１抗体 | |
| TWI821474B (zh) | Ｃｄ３抗體及其藥物用途 | |
| JP2021516974A5 (enExample) | ||
| JP2021525546A5 (enExample) | ||
| TW201827464A (zh) | 人程序性死亡受體ｐｄ－１的單株抗體及其片段 | |
| US12404333B2 (en) | Anti PD-L1 antibody and use thereof | |
| JP2018531219A6 (ja) | Ｐｄ−ｌ１抗体 | |
| CN114502591A (zh) | 靶向bcma的抗体、双特异性抗体及其用途 | |
| JP2013502913A5 (enExample) | ||
| RU2019104980A (ru) | Анти-icos антитела | |
| JP2022169504A5 (enExample) | ||
| RU2014103784A (ru) | Антитело, блокирующее agr2, и его применение | |
| TW202033218A (zh) | 多特異性蛋白分子 | |
| CN110642951B (zh) | 一种抗ca125糖类抗原的高中和活性纳米抗体及其应用 | |
| JP2026510999A (ja) | Ｃｄ１９／ｃｄ３８多重特異性抗体 | |
| JP2020533965A5 (enExample) | ||
| JP2020531003A5 (enExample) | ||
| CN112805302A (zh) | 抗BCMA单链抗体scFv及其制备方法和应用 | |
| EP4032908A1 (en) | Anti-pd-l1 antibody and pharmaceutical use thereof | |
| CN113549152A (zh) | 一种抗basigin人源化抗体及其应用 | |
| CN110563847A (zh) | 用于治疗性用途的免疫检查点抑制剂 | |
| JP2024534806A5 (enExample) | ||
| JP2013177317A (ja) | 抗ｐｄｇｆ受容体抗体 | |
| CN110563848A (zh) | 一种双特异性抗体及其用途 |